Phase 1/2 study of epacadostat in combination with durvalumab in patients with metastatic solid tumors

BACKGROUND: Targeting programmed cell death protein 1 (PD‐1) and indoleamine 2,3‐dioxygenase (IDO1) pathways is an appealing option for cancer treatment. METHODS: The open‐label, phase 1/2 ECHO‐203 study evaluated the safety, tolerability, and efficacy of the IDO1 inhibitor epacadostat in combinatio...

Descripción completa

Detalles Bibliográficos
Autores principales: Naing, Aung, Algazi, Alain P., Falchook, Gerald S., Creelan, Benjamin C., Powderly, John, Rosen, Seth, Barve, Minal, Mettu, Niharika B., Triozzi, Pierre L., Hamm, John, Zhou, Gongfu, Walker, Chris, Dong, Zhiwan, Patel, Manish R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
ORIGINAL ARTICLES
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10092291/
https://www.ncbi.nlm.nih.gov/pubmed/36309837
http://dx.doi.org/10.1002/cncr.34512

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10092291/
https://www.ncbi.nlm.nih.gov/pubmed/36309837
http://dx.doi.org/10.1002/cncr.34512

Ejemplares similares